Tecentriq Breakthrough: Roche's Immunotherapy Significantly Improves Outcomes for High-Risk Colon Cancer Patients
2025-06-06
Reuters
Roche's Tecentriq Shows Promise in Reducing Recurrence and Mortality in Colon Cancer In a significant advancement for the treatment of colon cancer, Roche's immunotherapy drug, Tecentriq (atezolizumab), has demonstrated remarkable results in a recen ...Read more
